Magnolia Neurosciences Corporation is a drug discovery and development company focused on
the creation of a novel class of neuroprotective medicines. The company endeavors to make
life-changing medicines for the benefit of patients and their families suffering from serious CNS
diseases. The company was launched by a $31M Series A investment by Accelerator Life
Science Partners in 2018 and was co-founded by world class researchers at The University of
Texas MD Anderson Cancer Center. The company’s offices are located in the Alexandria
Center for Life Science, New York City’s first and only premier life science campus. The
company also has a wholly owned subsidiary, Magnolia Tejas Corporation, based in Houston,
Texas that is focused on developing a novel therapy for chemotherapy-induced neurological
conditions.
